Johnson & Johnson
Enterprise Plan
View:
RJ
Welcome to your Competitive Intelligence Dashboard
Stay informed about the latest developments in your therapeutic areas of interest. Your dashboard is personalized based on your preferences.
Dashboard
Your Competitive Landscape
31
Total Alerts
12
Pipeline Updates
15
Clinical Trial Changes
7
Regulatory Updates
Recent Alerts
AbbVie announces positive Phase 3 results for upadacitinib in RA
3h ago
Clinical Trial
Pfizer receives FDA approval for new immunology treatment
6h ago
Regulatory
Merck's Keytruda shows positive results in new indication
1d ago
Clinical Trial
Amgen presents new data at ASCO 2025 conference
2d ago
Conference
Pipeline Tracker
Recent updates in your therapeutic areas of interest:
AbbVie's upadacitinib - Phase 3 results
Rheumatoid Arthritis | JAK inhibitor
Phase 3
Pfizer's PF-06650833 - New trial initiated
Psoriatic Arthritis | IRAK4 inhibitor
Phase 2
Merck's MK-1242 - Data presentation
Oncology | PD-1 inhibitor
Phase 3
Weekly Snapshot
Latest Snapshot
May 17, 2025
Next Snapshot
May 24, 2025
Key highlights from your latest weekly snapshot:
- 4 new clinical trials initiated in immunology
- FDA advisory committee meeting scheduled for AbbVie's RA therapy
- Merck presented positive data at ASCO 2025 conference
- New treatment guidelines published for Psoriatic Arthritis
Data Snacks
View All Data SnacksQuick insights from your competitive landscape:
JAK Inhibitor Landscape
4 competitors have JAK inhibitors in Phase 3 trials for RA, with potential approvals expected in 2026-2027.
Immunology Treatment Trends
Targeted biologics continue to dominate the pipeline, with 7 assets in late-stage development.
© 2025 CI Agent. All rights reserved.